ReviewClinical and vaccine immunology : CVI2015
Current Progress in Developing Subunit Vaccines against Enterotoxigenic Escherichia coli-Associated Diarrhea.
Review in Clinical and vaccine immunology : CVI, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 90 citations in OpenAlex.
- A 25-year landscape of Escherichia coli vaccine development: systematic review of human clinical studies.NPJ vaccines · 2026Article
- MecVax, an Epitope- and Structure-Based Broadly Protective Subunit Vaccine Against EnterotoxigenicMicroorganisms · 2025Review
- Recent progress in enterotoxigenicInfection and immunity · 2025Review
- Chimeric Fimbrial Multiepitope Antigen Fused to Double-Mutant LT (dmLT) Induces Antibodies That Inhibit EnterotoxigenicAnimals : an open access journal from MDPI · 2025Article
- Immunogenicity and preclinical efficacy characterization of ShecVax, a combined vaccine againstInfection and immunity · 2025Article
- A RecombinantInternational journal of molecular sciences · 2024Article
- Assessment of groundwater quality for human consumption and its health risks in the Middle Magdalena Valley, Colombia.Scientific reports · 2024Article
- Production of a new tetravalent vaccine targeting fimbriae and enterotoxin of enterotoxigenicCanadian journal of veterinary research = Revue canadienne de recherche veterinaire · 2024Article
- GM1a ganglioside-binding domain peptide inhibits host adhesion and inflammatory response of enterotoxigenic Escherichia coli heat-labile enterotoxin-B in HCT-8 cells.Scientific reports · 2023Article
- Site-Specific Analysis of the Incidence Rate of Enterotoxigenic Escherichia coli Infection Elucidates an Association with Childhood Stunting, Wasting, and Being Underweight: A Secondary Analysis of the MAL-ED Birth Cohort.The American journal of tropical medicine and hygiene · 2023Article
- Article
- Colonizing and Virulence Factors in Enterotoxigenic Escherichia coli from Peru.The American journal of tropical medicine and hygiene · 2023Article
- Development of a new candidate vaccine against piglet diarrhea caused byOpen life sciences · 2023Article
- Heterologous Assembly of the Type VI Secretion System Empowers Laboratory Escherichia coli with Antimicrobial and Cell Penetration Capabilities.Applied and environmental microbiology · 2022Article
- A multi-epitope fusion antigen candidate vaccine for Enterotoxigenic Escherichia coli is protective against strain B7A colonization in a rabbit model.PLoS neglected tropical diseases · 2022Article
- Pig vaccination strategies based on enterotoxigenic Escherichia coli toxins.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2021Review
- Assessment of probiotic adhesion and inhibitory effect on Escherichia coli and Salmonella adhesion.Archives of microbiology · 2021Article
- Preclinical Characterization of Immunogenicity and Efficacy against Diarrhea from MecVax, a Multivalent Enterotoxigenic E. coli Vaccine Candidate.Infection and immunity · 2021Article
- Evaluation of a Novel Mucosal Administered Subunit Vaccine on Colostrum IgA and Serum IgG in Sows and Control of EnterotoxigenicFrontiers in veterinary science · 2021Article
- Role of Recent Therapeutic Applications and the Infection Strategies of Shiga Toxin-ProducingFrontiers in cellular and infection microbiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Diarrhea continues to be a leading cause of death in children <5 years of age, and enterotoxigenic Escherichia coli (ETEC) is the most common bacterial cause of children's diarrhea. Currently, there are no available vaccines against ETEC-associated diarrhea. Whole-cell vaccine candidates have been under development but require further improvements because they provide inadequate protection and produce unwanted adverse effects. Meanwhile, a newer approach using polypeptide or subunit vaccine candidates focusing on ETEC colonization factor antigens (CFAs) and enterotoxins, the major virulence determinants of ETEC diarrhea, shows substantial promise. A conservative CFA/I adhesin tip antigen and a CFA MEFA (multiepitope fusion antigen) were shown to induce cross-reactive antiadhesin antibodies that protected against adherence by multiple important CFAs. Genetic fusion of toxoids derived from ETEC heat-labile toxin (LT) and heat-stable toxin (STa) induced antibodies neutralizing both enterotoxins. Moreover, CFA-toxoid MEFA polypeptides, generated by fusing CFA MEFA to an STa-LT toxoid fusion, induced antiadhesin antibodies that broadly inhibited adherence of the seven most important ETEC CFAs associated with about 80% of the diarrhea cases caused by ETEC strains with known CFAs. This same antigen preparation also induced antitoxin antibodies that neutralized both toxins that are associated with all cases of ETEC diarrhea. Results from these studies suggest that polypeptide or subunit vaccines have the potential to effectively protect against ETEC diarrhea. In addition, novel adhesins and mucin proteases have been investigated as potential alternatives or, more likely, additional antigens for ETEC subunit vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.